5 -羟色胺前体在慢性原发性头痛。一项双盲交叉研究与L-5-hydroxytryptophan与安慰剂。
文章的细节
-
引用
复制到剪贴板 -
De Benedittis G, Massei R
5 -羟色胺前体在慢性原发性头痛。一项双盲交叉研究与L-5-hydroxytryptophan与安慰剂。
J Neurosurg Sci . 1985 Jul-Sep; (3): 239 - 48。
- PubMed ID
-
3913752 (在PubMed]
- 文摘
-
5 -羟色胺(5 -)在调解中扮演着关键角色下行抑制系统疼痛和偏头痛的病理生理学。先前的研究关于使用5-Hydroxytryptophan (5-HTP), 5 -的活性前体,治疗慢性原发性头痛(CPH)到目前为止一直不确定。为了评估血清素的功效活性前体慢性头痛预防、双盲交叉研究进行了31 CPH患者,比较L-5-HTP和安慰剂。临床症状包括:(一)偏头痛患者(16);(b)混合头痛(6例);(c)心因性头痛(5例);(d)肌肉收缩头痛(4例)。L-5-HTP管理两个月的每日剂量400毫克订单。头痛的严重程度和频率减少病人服用活性药物和安慰剂。情绪模式也被考虑。L-5-HTP被证明是比安慰剂更有效减少头痛频率和严重程度,但是差异没有统计学意义。 Favourable responses (greater than 50% average reduction in headache symptoms) were obtained in 48% of the cases after the second month of treatment. No significant difference in therapeutic response was observed as related to different clinical syndromes, except for psychogenic headache patients, who responded poorly to the active drug. Side effects, experienced in 19% of the cases, were generally mild and transient. We conclude that L-5-HTP is a medication of moderate efficacy and remarkable safety, providing us with another alternative approach to CPH prophylaxis.
beplay体育安全吗DrugBank数据引用了这篇文章
- 药物